Planned Solutions’s vTv Therapeutics VTVT Stock Holding History

Planned Solutions’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25	Closed	-$339	–	632
2024 Q3	$339	Buy	+25	New	+$415	﹤0.01%	619

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Planned Solutions's VTVT Position: Q4 2024 in Review

Planned Solutions sold out of vTv Therapeutics (VTVT) in Q4 2024, closing a stake of 25 shares — an estimated $339 sold.

Planned Solutions first reported a position in VTVT in Q3 2024 and held it in 1 quarter. The position peaked at $339 in Q3 2024. 17 funds tracked by Wall St. Rank hold VTVT as of Q4 2024.

Planned Solutions reported no remaining vTv Therapeutics position as of Q4 2024 after selling out during the quarter.
Planned Solutions sold 25 vTv Therapeutics shares in Q4 2024, an estimated $339.
Planned Solutions first reported a position in vTv Therapeutics in Q3 2024 and held it in 1 quarter.
Planned Solutions's vTv Therapeutics position peaked at $339 in Q3 2024.
17 funds tracked by Wall St. Rank held vTv Therapeutics as of Q4 2024.

Based on Planned Solutions's 13F filing for Q4 2024, filed 17 Jan 2025.